A Randomized, Open-Label, Phase 3 Study of ZL-1310, a DLL3 Antibody-Drug Conjugate (ADC), Compared to Investigator's Choice Therapy in Participants With Relapsed Small Cell Lung Cancer
A Randomized, Open-Label, Phase 3 Study of ZL-1310, a DLL3 Antibody-Drug Conjugate (ADC), Compared to Investigator's Choice Therapy in Participants With Relapsed Small Cell Lung Cancer
The purpose of this study is to evaluate the efficacy and safety of ZL-1310 compared to Investigator's Choice Therapy in participants with relapsed Small Cell Lung Cancer.
Inclusion Criteria:
Exclusion Criteria:
study-ZL-1310-003@zailaboratory.com650-360-1601
Shimosuga, Tochigi 321-0293, Japan
Bunkyō-Ku, Tokyo 113-8603, Japan
Bunkyō-Ku, Tokyo 113-8677, Japan
Koto-Ku, Tokyo 135-8550, Japan
Shinjuku-Ku, Tokyo 162-8655, Japan